WuXi Biologics Launches High-Concentration Formulation Platform WuXiHigh™2.0

• WuXi Biologics has launched WuXiHigh™2.0, a high-throughput formulation development platform supporting biologic concentrations up to 230mg/mL.

• The platform reduces viscosity by up to 90%, enabling greater injection efficiency and improved manufacturing outcomes.

WuXi Biologics, a global CRDMO, has introduced WuXiHigh™2.0, a high-throughput formulation development platform for biologics with protein concentrations up to 230mg/mL. The platform is designed to meet increasing industry demand for high-concentration therapies that improve dosing and patient compliance.

The announcement responds to a key challenge in biologics development: high viscosity and aggregation issues in formulations exceeding 100mg/mL. WuXiHigh™2.0 addresses these constraints by using over 24 proprietary excipient combinations to reduce viscosity by up to 90%, without compromising stability or injectability.

The platform integrates high-throughput instrumentation to predict viscosity and aggregation risks early in the development cycle. This data-driven process supports more efficient excipient selection, reduces material usage, and shortens timelines for formulation development. The technology also supports UF/DF at viscosities up to 100 cP and precision filling at up to 50 cP, facilitating a smooth transition from clinical to commercial manufacturing.

Commenting on the launch, Dr. Chris Chen, CEO of WuXi Biologics, said: “WuXiHigh™2.0 represents a transformative technology platform for next-generation biologics with high-concentration formulations. Its ability to enhance concentration while reducing viscosity redefines industry benchmarks, and more importantly elevates patient experience without compromising drug efficacy.”

WuXiHigh™2.0 adds to the company’s growing suite of CDMO solutions aimed at advancing biologic formulation, drug product manufacturing, and global development for its clients.